YEARS IN CANADA AND STILL COUNTING!



Over 1.1 million


patient-years of experience worldwide combined across all indications 1,3

XOLAIR® (omalizumab) is indicated for:

- Adult and pediatric patients (6 years of age and above) with moderate
 to severe persistent asthma who have a positive skin test or *in vitro*reactivity to a perennial aeroallergen and whose symptoms are inadequately
 controlled with inhaled corticosteroids.
- The treatment of adults and adolescents (12 years of age and above) with chronic idiopathic urticaria (CIU) who remain symptomatic despite H1 antihistamine treatment.

Please consult the Product Monograph at www.novartis.ca/XolairMonograph for important information relating to contraindications, warnings, precautions, adverse reactions, drug interactions, conditions of clinical use, and dosage and administration information. The Product Monograph is also available by calling 1-800-363-8883.

References: 1. Notice of Compliance. Health Canada. 2004. **2.** XOLAIR® Product Monograph. Novartis Pharmaceuticals Canada Inc., January 23, 2019. **3.** Novartis Data on File. 2020.







XOLAIR is a registered trademark. Product Monograph available on request.

© 2020 Novartis Pharmaceuticals Canada Inc.

